Cobenfy (KarXT) is an innovative oral capsule medication approved by the U.S. Food and Drug Administration (FDA) in 2024, specifically indicated for the treatment of schizophrenia in adults. This medication features a unique combined formulation, consisting of Xanomeline (a muscarinic agonist) and Trospium Chloride (a muscarinic antagonist), and exerts its therapeutic effects through a precise dose-balanced mechanism.
Indications for Cobenfy (KarXT)
Treatment of Schizophrenia
In accordance with the complete prescribing information approved by the FDA, Cobenfy is specifically indicated for the treatment of schizophrenia in adults.
Mechanism of Action
Cobenfy’s therapeutic mechanism is based on its unique component combination: Xanomeline, as a muscarinic agonist, exerts its effects primarily by activating M1 and M4 muscarinic acetylcholine receptors in the central nervous system.
Trospium Chloride, as a muscarinic antagonist, mainly antagonizes muscarinic receptors in peripheral tissues, effectively reducing peripheral side effects.
Specifications and Properties of Cobenfy (KarXT)
Dosage Specifications
50 mg/20 mg: Contains 50 mg of Xanomeline and 20 mg of Trospium Chloride.
100 mg/20 mg: Contains 100 mg of Xanomeline and 20 mg of Trospium Chloride.
125 mg/30 mg: Contains 125 mg of Xanomeline and 30 mg of Trospium Chloride.
Physical Characteristics
Capsule Color Coding: 50 mg/20 mg capsules are pale yellow, 100 mg/20 mg capsules are brown, and 125 mg/30 mg capsules are Swedish orange.
Each dosage strength capsule is marked with the corresponding Karuna logo and dosage information.
The drug ingredients adopt a unique granulation technology to ensure precise control of drug release.
Packaging Information
Bottle Packaging: Each bottle contains 60 capsules.
Initial Dose Packaging: Specifically designed for the 100 mg/20 mg dosage strength.
Different dosage strengths correspond to specific National Drug Codes (NDCs) respectively.
Active Ingredients
Xanomeline Tartrate: Chemically classified as a pyridine derivative.
Trospium Chloride: Classified as a quaternary ammonium compound.
Excipient Composition
Xanomeline granules contain ascorbic acid, microcrystalline cellulose, and talc.
Trospium Chloride granules contain lactose monohydrate, microcrystalline cellulose, and talc.
Capsule shells contain black iron oxide, hypromellose, red iron oxide, titanium dioxide, and yellow iron oxide.
Storage Methods for Cobenfy (KarXT)
Temperature Control
Cobenfy should be stored at standard room temperature (20°C to 25°C / 68°F to 77°F).
Brief deviations to a temperature range of 15°C to 30°C (59°F to 86°F) are permitted, but prolonged exposure to extreme temperatures should be avoided.
Precautions
Protect the medication from moisture and direct sunlight.
Keep the bottle cap tightly closed to prevent drug contamination and loss of active ingredients.
Store the medication in a secure location out of the reach of children.
Special Storage Requirements
After opening, the medication should be stored in its original packaging.
Avoid storing the medication in high-humidity areas such as bathrooms.
The medication should not be frozen or placed in high-temperature environments (e.g., on a car dashboard).
